← All trials
NCT05644184
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Dec 9, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 1683
- Arms / groups
- 12 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PATHLead sponsor
- Bill and Melinda Gates FoundationCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
- International Center for Diarrheal Disease ResearchOverall official - principal investigator
- PT Bio FarmaCollaborator
- International Center for Diarrheal Disease ResearchOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.